Pharma Is Wasting Millions on Product Websites Nobody Uses

Glowing digital interface connecting documents, users, databases, and global networks

Pharma has a website problem nobody wants to talk about. Companies continue to spend millions of dollars building, redesigning, maintaining, testing, and promoting massive branded product websites as if patients are sitting at home thinking, “I really want to spend the next 20 minutes exploring the manufacturer’s website.” They aren’t. Patients still look for drug and health information. They’ve changed where and how they look for it. Yet pharma’s digital strategy largely remains stuck in 2015.

This year I’ve done a lot of website analysis for clients, and one finding is becoming standard: website visitors aren’t using 90% of a product website’s pages. Online health seekers come, get the essential information, and leave.

It’s time to acknowledge the shift

The shift is becoming impossible to ignore. KFF reported last year that 32% of U.S. adults had turned to AI chatbots for physical or mental health information or advice in the previous 12 months. 29% had used AI to research physical health information specifically. More revealing is what they asked: When seeking health information from AI, 27% of all adults said they had looked up symptoms or general information about health conditions. 19% used AI to understand medical tests, lab results, or diagnoses. Another 19% sought to understand and compare treatment options, and 16% have used AI to help decide whether they should see a doctor.

Adoption is moving quickly. By June last year, KFF found American adults were using AI tools or chatbots for health information at least monthly, nearly double the 17% measured just six months earlier in 2024. Social media was at 31%. Meaning AI has essentially caught social media as a regular go-to source for health information. ChatGPT, Gemini, Claude, and other AI tools went from being curiosities to becoming regular health-information resources for almost three in ten adults in roughly two years.

Pew Research Center’s August report adds to the narrative. Four in ten Americans now say they use AI chatbots to diagnose symptoms. Roughly similar shares say they rely on AI to better understand information they’ve received from their healthcare provider including a diagnoses or laboratory results. And nearly all of the people who use chatbots to find health information say the information is at least somewhat helpful. That’s a fundamental shift in how patients journey for health information.

But…

Traditional search is changing just as rapidly. The old digital patient journey looked something like this: patient develops symptoms → patient searches Google → patient clicks a link → patient visits a website. Today, Google increasingly gives patients the answer itself through AI summaries. While patients can now bypass search altogether and ask Google’s AI assistant a complicated question.

The implication for pharma is huge: visiting a website is no longer a guaranteed part of the patient journey.

And we’re not just talking healthcare. Adobe analyzed over 1 trillion visits to U.S. retail websites last year and documented just how rapidly AI is inserting itself between consumers and websites. Traffic coming from generative AI sources grew 1,200% between July 2024 and February 2025. Visitors arriving through AI referrals also behaved differently. They spent 8% more time on page, viewed 12% more total pages, and had a 23% lower bounce rate than visitors arriving from other channels.

Look at most pharma product websites, and it’s easy to see how dramatically the industry is missing the shift. There are disease-state resources, patient stories, MOA animations, FAQs, downloadable discussion guides, videos, newsletters, symptom checkers and lifestyle advice, treatment education, list price info, insurance coverage details, copay savings instructions, and gigantic walls of copy somebody convinced the brand team conveyed “engagement.” Then analytics teams proudly share time-on-site and pages-per-session as if forcing a patient through seven pages to answer one question is somehow a positive reflection of digital success.

It isn’t.

Much of that content probably doesn’t need to exist.

Pharma brands should ask themselves a brutally simple question: What can we provide that nobody else can?

The answer is probably not a 1,500-word blog post about diabetes. That’s Mayo Clinic’s job. It’s not another rundown of migraine symptoms. Patient resource sites and medical journals already do hundreds of those. AI will increasingly be able to summarize those ten articles into a personalized answer for patients in seconds.

The one thing pharma brands can provide that nobody else can is information about their drug.

Focus On Gaps

Pharma should retract from everywhere else and own what it does best. What’s that? Medical information about its products.

Tell patients what the drug is approved to treat. Explain how it works without requiring a medical degree. Show what clinical trials have demonstrated, don’t forget what they haven’t, and explain major side effects. Make instructions for use incredibly clear. Do the same for major risks. Price information, insurance coverage details, copay savings, and patient support information should all be ridiculously easy to find. Obviously include prescribing info and safety information. Then stop getting in the way.

That might leave drug websites with 10 really good pages of content instead of 60 mediocre ones.

Instead, pharma will keep justifying bloated websites and huge content libraries. Website visits and time on site won’t magically increase overnight. But the overall cost to serve digital patients would probably plummet. No more constantly defending irrelevant “jewelry” content just because you wrote it. Fewer resources required to create and update new content. And brands could finally treat website analytics like traditional marketing measurement tools—optimized around business outcomes instead of web-specific vanity metrics.

Not having the best website won’t stop patients from researching their health online.

Website With AI Information?

Pharma needs to start thinking beyond the website. While we obsess over digital patients, real humans are asking Google and AI systems questions. AI isn’t competitive differentiation.

While Pharma focuses on visitors and sessions, real patients are googling “What’s driving insurance premiums up?”

“How do layoffs affect my benefits?”

“Should I tell my family about my cancer diagnosis?”

Patients are searching for answers to a seemingly limitless number of questions online. Google is showing answers and presenting information sources right now, whether pharma copies and pastes another version onto its website or not.

If pharma wants to stay involved in that process, it needs to optimize for AI and Google just as much as organic patients.

Changing Attitudes

Pharma companies aren’t getting fewer visits because nobody is researching prescription medications online. They’re getting fewer visits because the patient’s first stop isn’t necessarily a decision they control. We need to stop thinking about our websites as patient destinations. Information destinations.

Patients won’t stop needing access to drug pricing information. Compound tutorials. Treatment comparisons. Scientific research. Patient stories. Manufacturing videos. Etc, etc, etc. They just won’t always get that information from the pharma company’s website.

Design digital experiences that let patients find answers quickly. And let patients go.

The shift is here.

The pharma industry can either embrace it or continue to mandate that designers produce Websites that resemble a destination that nobody goes to.

Patients won’t care which website you built for them. They only care about how well it answers their questions.

When was the last time you found a medication’s website particularly useful?

About Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

View all posts by Richard Meyer →

Leave a Reply